Lenalidomide created quite a stir on Wall Street on July 11, 2013 when shares of Celgene’s Revlimid, the brand name of Lenalidomide, soared. The frenzy occurred after Celgene released data from the Phase 3 study of Lenalidomide, revealing the great success of this blood cancer drug. Lenalidomide proved in Phase 3 studies to effectively halt[…]
Lenalidomide Causes a Stir on Wall Street
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Patent Expiration 2019 Tags: 191732-72-6anemiadexamethasoneLenalidomidemantle cell lymphomamultiple myeloma Jul 24, 2013
Prepare for the Future Exaction of Oncology Products
Drug Research & Development API, Immunological Agent, Immunosuppressant Tags: 159351-69-6191732-72-6acute lymphoblastic leukemiaBortezomibEverolimusLenalidomideleukemiamultiple myeloma Jul 05, 2012
The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007. Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]
Immunosuppressive Drugs for Transplant – Treatments, Side Effects, and Future Research & Development
Drug Research & Development API, Immunological Agent, Immunosuppressant Tags: 159351-69-6191732-72-6EverolimusFingolimod HydrochlorideImmunosuppressantLenalidomideMethotrexateSirolimus Mar 15, 2011
For organ transplant patients, the normally protective immune response can threaten the longevity and function of the transplanted organ. Currently, organ transplant patients must take immunosuppressive or anti-rejection medication to prevent the immune system from fighting against the new, transplanted organ. Often a choice is made between the certain damage of a steroid drug, and[…]
